Blog
RSS FeedPosted by Michael Wonder on 04 Jan 2017
The changing face of clinical trials: the large pharmaceutical company perspective
4 January 2017 - Large pharmaceutical companies conduct clinical trials to evaluate efficacy and identify safety issues for candidate drugs as ...
Posted by Michael Wonder on 30 Dec 2016
FDA completes guidance on the development of biosimilars
29 December 2016 - Drug makers received guidance from the FDA on 28 December on the development of biosimilar medicines. ...
Posted by Michael Wonder on 27 Dec 2016
Negative control outcomes: a tool to detect bias in randomised trials
27 December 2016 - Investigators have several design, measurement, and analytic tools to detect and reduce bias in epidemiological studies. One ...
Posted by Michael Wonder on 22 Dec 2016
FDA officials call for including adolescents in adult oncology trials
20 December 2016 - A team of officials at the US FDA are calling for a "culture shift" by drug ...
Posted by Michael Wonder on 20 Dec 2016
Harnessing the U.S. taxpayer to fight cancer and make profits
19 December 2016 - Enthusiasm for cancer immunotherapy is soaring, and so is Arie Belldegrun’s fortune. ...
Posted by Michael Wonder on 18 Dec 2016
Tailored scientific advice to support step-by-step development of new biosimilars
16 December 2016 - Pilot project to commence in February 2017. ...
Posted by Michael Wonder on 15 Dec 2016
A new type of molecular medicine may be needed to halt cancers
16 December 2016 - Doctors must look to proteins rather than genes to tackle tumours. ...
Posted by Michael Wonder on 15 Dec 2016
Transforming evidence generation to support health and health care decisions
14 December 2016 - Making better choices about health and health care requires the best possible evidence. Unfortunately, many of the ...
Posted by Michael Wonder on 14 Dec 2016
The 21st Century Cures Act — a view from the NIH
14 December 2016 - The Cures Act, formally known as H.R. 34 or the 21st Century Cures Act, passed overwhelmingly in ...
Posted by Michael Wonder on 14 Dec 2016
Obama signs $6.3 billion law for cancer research, drug treatment
14 December 2016 - President Barack Obama has signed into law legislation that makes new investments in cancer research and battling ...
Posted by Michael Wonder on 13 Dec 2016
EMA hosts workshop on adaptive pathways
13 December 2016 - Broad range of stakeholder questions addressed. ...
Posted by Michael Wonder on 12 Dec 2016
Lives and profits in the balance: the high stakes of medical patents
11 December 2016 - Decades after Dr. Jonas Salk opposed patenting the polio vaccine, the pharmaceutical industry has changed. What does ...
Posted by Michael Wonder on 08 Dec 2016
Interpreting geographic variations in results of randomised, controlled trials
7 December 2016 - Clinical triallists generally accept the premise that surprising results in subgroups of a randomised, controlled trial most ...
Posted by Michael Wonder on 08 Dec 2016
1 patient, 7 tumours and 100 billion cells equal 1 striking recovery
7 December 2016 - The remarkable recovery of a woman with advanced colon cancer, after treatment with cells from her ...
Posted by Michael Wonder on 06 Dec 2016
Twelfth joint EMA/EUnetHTA dialogue meeting
5 December 2016 - The 12th joint meeting between the EMA and the European network for Health Technology Assessment (EUnetHTA) will ...